降糖药物剂型研究进展  

Research Progress on Hypoglycemic Drug Formulations

作　　者：庄忠宝 邹芳[2] ZHUANG Zhong-bao;ZOU Fang(Department of Pharmacy,Hebei North University,Hebei Zhangjiakou 075000;Department of Respiration,the First Affiliated Hospital of Hebei North university,Heibei Zhangjiakou 075000,China)

机构地区：[1]河北北方学院药学系,河北张家口075000 [2]河北北方学院第一附属医院呼吸内科,河北张家口075000

出　　处：《广州化工》2020年第14期16-18,共3页GuangZhou Chemical Industry

摘　　要：糖尿病是以高血糖水平为特征的代谢性疾病,其病因和发病机制尚不清楚,大量实验研究表明,其主要由遗传因素、自身免疫以及环境因素等共同作用的结果。随着降糖药物制剂研究的发展,许多的剂型被研发出来用于提高生物利用度,并降低药物在治疗过程中所带来的副作用。通过对降糖药物剂型近些年来相关报道进行综述,以期为寻找降糖药物新剂型的开发提供参考依据。Diabetes mellitus is a metabolic disorders characterized by high blood concentration level,and its etiology and pathogenesis are not clear.Many researches suggest that diabetes is the result of genetic factors,autoimmune factors and environmental factors.With the development of research on hypoglycemic drugs,many dosage forms were developed to improve the bioavailability and reduce the side effects of drugs in the treatment process.In order to provide reference for the development of new drug formulations,the related reports in recent years were reviewed.

关 键 词：糖尿病 降糖药物 剂型研究 

分 类 号：TQ944.9[化学工程]